Compare the stated charge before the monthly copper-peptide price

Put the total next to the monthly display

Bounce Back's current offer shows $64.99 per month with a $195 three-month total. The one-month option shows $79.99 per month beside an $80 total. These small differences remain part of the observed page; we do not replace the seller's displayed totals with a reconstructed amount and present that as a tested charge. Current Bounce Back offer

The CoreAge evidence review also records the starting price on its product page. A starting monthly display should not be treated as a documented standalone purchase available on different terms. The named option and complete stated charge belong together whenever the price is repeated.

Distinguish a comparison unit from a payment arrangement

The phrase per month can communicate how an offer is presented without proving that money is collected in monthly installments. The current public page includes plan totals and advertises no auto-billing. We have not followed a prescription assessment or inspected the final payment terms for an individual order.

Those limits should remain visible rather than be filled with assumptions about a subscription. A statement about an advertised billing arrangement is not evidence of a successful cancellation, a refund or a completed shipment. The public-record shortlist compares what is documented without claiming that those service outcomes were tested.

A period is not the amount inside the package

A three-month plan and a thirty-milliliter bottle are different descriptions. The first does not independently reveal the number of containers or the contents of each; the second does not establish how long a person will use the product. The reviewed Bounce Back offer leaves the exact supplied quantity unresolved.

For that reason, this guide does not estimate an application amount or calculate a shared monthly consumption rate. It would require assumptions about instructions and use that the public price alone cannot support. The absence of a comparable quantity is a substantive limit, not a blank field that should be silently replaced with a convenient estimate.

Attach each serum price to the checked size

The Ordinary's current US record identifies a 30 mL option at a promotional $28.80, with $32 shown as the reference price. NIOD's CAIS record shows $62 for 15 mL, and its public size-selection response confirms $93 for 30 mL. These are dated observations for particular variants, not guaranteed future or delivered totals. The Ordinary and NIOD

The Ordinary review and NIOD review preserve those identities. A price near a different product card, an unselected size or a companion recommendation should not be assigned to the bottle being reviewed. Similar packaging names do not make the offers interchangeable.

Keep additional products and service terms separate

NIOD recommends a separate hydration product alongside its serum. That suggestion does not establish that the companion is included in the CAIS bottle price or required for every reader. Similarly, a prescription offer's advertised shipping and review process should not be treated as the same purchase format as a cosmetic bottle.

Bounce Back advertises shipping included and a refund if treatment is not approved. Those are seller terms, not outcomes verified by this publication. An accurate comparison identifies what the offer says and what the reviewed record leaves unresolved; it does not promise eligibility, a particular refund experience or a professional response for a reader.

Do not let a percentage become a value calculation

A larger printed peptide number cannot establish a greater amount of clinically useful benefit per dollar. Bounce Back's advertised 2% lacks the analytical specification needed for a direct comparison with the differently described serum systems. NIOD's separate 1% GHK-Cu and 1% GHK components also should not be relabeled as 2% copper peptide.

The grade-and-purity guide explains the identity gap, while the firmness guide addresses outcome differences. Neither evidence nor product value can be reduced to a ratio of a marketing percentage and a price. This page provides no potency or cost calculator.

State what the record can and cannot conclude

The public pages establish particular plan displays and particular bottle prices. They do not establish an equal monthly amount used, a completed order charge, the same type of clinical service or the same measured result. A ranking that ignores those differences would appear more precise than the underlying information.

The claim reader keeps a price's unit and missing evidence visible. A useful question asks which exact option, total, quantity and conditions apply to the quoted offer. Until those are established, the fair conclusion is a comparison of unlike public records, not a finding that one preparation supplies the most treatment for the money.

The expanded product reading also includes NEOVA, Osmotics and Good Molecules. Follow these reviews to establish which item a price inquiry concerns before comparing offers elsewhere. They are reading destinations, without a promise that their displayed amounts buy equivalent quantities or services. Keep the product record separate from the eventual checkout total and avoid projecting an unspecified container into an assumed number of months. A cost comparison needs its own documented units. The CoreAge offer record remains the attributed source for the offer examined in this guide, rather than a verified transaction or a benchmark for every linked brand.